These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28057111)

  • 1. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
    Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
    Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
    Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
    Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
    BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
    Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
    PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
    Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
    Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.
    de Soárez PC; Sartori AM; Freitas AC; Nishikawa ÁM; Novaes HM
    PLoS One; 2015; 10(6):e0130217. PubMed ID: 26114297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
    Mo X; Gai Tobe R; Liu X; Mori R
    Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
    Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
    Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
    De Graeve D; Verhaegen J; Ament A; Baltussen R
    Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
    Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
    Front Public Health; 2021; 9():647725. PubMed ID: 34109145
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
    Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
    JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan.
    Jiang Y; Yang X; Taniguchi K; Petigara T; Abe M
    J Med Econ; 2018 Jul; 21(7):687-697. PubMed ID: 29723081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.